IRINOTECAN Drug Patent Profile
✉ Email this page to a colleague
When do Irinotecan patents expire, and what generic alternatives are available?
Irinotecan is a drug marketed by Accord Hlthcare, Actavis Totowa, Chartwell Rx, Cipla Ltd, Emcure Pharms Ltd, Epic Pharma Llc, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hengrui Pharma, Hikma Farmaceutica, Hisun Pharm Hangzhou, Hospira, Intas Pharms Usa, Novast Labs, Pliva Lachema, Qilu Pharm Hainan, Sandoz, Shilpa, Sun Pharma Global, Teva Pharms Usa, West-ward Pharms Int, and Zennova. and is included in twenty-six NDAs.
The generic ingredient in IRINOTECAN is irinotecan hydrochloride. There are thirty-three drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the irinotecan hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Irinotecan
A generic version of IRINOTECAN was approved as irinotecan hydrochloride by ACTAVIS TOTOWA on February 27th, 2008.
Summary for IRINOTECAN
US Patents: | 0 |
Applicants: | 23 |
NDAs: | 26 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for IRINOTECAN |
DailyMed Link: | IRINOTECAN at DailyMed |